Analysis10k / Blog
EN한국어ES

Public companies, decoded straight from their own filings.

Every article on Analysis10k starts with a 10-K, a 10-Q, or an earnings call transcript — never a headline. We publish three angles per company: what it does, how its story has changed, and what its stock price is betting on.

Latest posts

View all posts →
LLY
Company Snapshot

Eli Lilly (LLY): What This Company Actually Does

A plain-English read of Eli Lilly's business model, built directly from its SEC filings — no hype, just where the money comes from.

2026-09-28
LLY
The Story

Eli Lilly's Last Three Years: A Company That Couldn't Keep Up With Its Own Success

How Mounjaro and Zepbound demand kept outrunning Eli Lilly's own guidance — and how the two moments that looked like trouble both turned into launching pads for the next raise.

2026-09-28
LLY
Reverse DCF

What LLY's Stock Price Is Really Betting On

Reverse-engineering the growth rate Eli Lilly's current share price already assumes — and why the answer swings wildly depending on which year's cash flow you use as a baseline.

2026-09-28
ABBV
Company Snapshot

AbbVie (ABBV): What This Company Actually Does

A plain-English read of AbbVie's business model, built directly from its SEC filings — no hype, just where the money comes from.

2026-09-27
ABBV
The Story

AbbVie's Last Three Years: 'Raising Guidance' While the Number Keeps Falling

How a CEO transition and a buying spree turned AbbVie's own guidance language into a puzzle worth decoding every quarter.

2026-09-27
ABBV
Reverse DCF

What ABBV's Stock Price Is Really Betting On

Reverse-engineering the growth rate AbbVie's current share price already assumes — and checking it against five years of shrinking free cash flow.

2026-09-27
173 posts published58 companies covered3 post types per company — Snapshot · Story · Reverse DCF